Expressão imuno-histoquímica do ativador de plasminogênio do tipo uroquinase e seu receptor em carcinoma epidermoide de língua oral e sua relação com parâmetros clínico-patológicos

Squamous cell carcinoma (SCC ) is the most common malignancy of the oral cavity (OSCC), with a high mortality rate. Due to this, the discovery of biomarkers that facilitate the understanding of the biological behavior of the tumor and improve treatment is necessary. Urokinase type plasminogen activator (uPA) and its receptor, uPAR, are responsible for the proteolysis of structures of the basement membrana and extracellular matrix, facilitating tumor invasion. This study aims to assess the immuno expression of these proteins in 46 cases of squamous cell carcinoma of the oral tongue (OTSCC). These results were related to the presence of metastasis, clinical TNM staging, locoregional recurrence, outcome of the lesion and histological grading. Immunostaining of each case was evaluated semiquantitatively, in the front of invasion and center of the tumor, in which scores were assigned: 0 (0% of positive cells), 1 (1-10% of positive cells), 2 (11 -50% positive cells) and 3 (more than 50% positive cells). The expression of uPA was observed in 93.5% (n=43) of the cases in the front of invasion, with predominance of score 2 (n=16; 34.8%) and in 67.9% (n=31) of the cases in the center of the tumor, with predominance of score 1 (n=15; 32.6%). Overall, the immunoexpression of uPA was not associated with clinical parameters. Regarding the malignant histological grading, a higher expression of uPA was observed in cases of high-grade malignancy comp ared to low-grade malignancy (p=0.05). Regarding the morphological parameters, increased expression of uPA was observed in the worst mode of invasion (p=0.03 ). The expression of uPAR was observed in 73.9% of cases in the front of invasion, with a predominance of score 1 (n=21; 45.6 %), and in 47.5% (n=21) of the cases in the center of the tumor, with a predominance of score 0 (n=25; 54.4%). Although no statistical differences were observed in relation to lymph node metastasis, clinical TNM staging, outcome, and histological grading, there was a higher expression of uPAR in cases with locoregional recurrence (p=0.04). Regarding the tumor intra -localization, it was observed an increased expression of uPA and uPAR at the front of invasion in relation to the center of the tumor (p<0.001). Regarding the correlation between uPA and uPAR, there was no statistical sign ificance. Based on these results, it is suggested that uPA and uPAR are involved in the progression of CELO, mainly in the deeper region of the tumor.

Expressão imuno-histoquímica do ativador de plasminogênio do tipo uroquinase e seu receptor em carcinoma epidermoide de língua oral e sua relação com parâmetros clínico-patológicos

Squamous cell carcinoma (SCC ) is the most common malignancy of the oral cavity (OSCC), with a high mortality rate. Due to this, the discovery of biomarkers that facilitate the understanding of the biological behavior of the tumor and improve treatment is necessary. Urokinase type plasminogen activator (uPA) and its receptor, uPAR, are responsible for the proteolysis of structures of the basement membrana and extracellular matrix, facilitating tumor invasion. This study aims to assess the immuno expression of these proteins in 46 cases of squamous cell carcinoma of the oral tongue (OTSCC). These results were related to the presence of metastasis, clinical TNM staging, locoregional recurrence, outcome of the lesion and histological grading. Immunostaining of each case was evaluated semiquantitatively, in the front of invasion and center of the tumor, in which scores were assigned: 0 (0% of positive cells), 1 (1-10% of positive cells), 2 (11 -50% positive cells) and 3 (more than 50% positive cells). The expression of uPA was observed in 93.5% (n=43) of the cases in the front of invasion, with predominance of score 2 (n=16; 34.8%) and in 67.9% (n=31) of the cases in the center of the tumor, with predominance of score 1 (n=15; 32.6%). Overall, the immunoexpression of uPA was not associated with clinical parameters. Regarding the malignant histological grading, a higher expression of uPA was observed in cases of high-grade malignancy comp ared to low-grade malignancy (p=0.05). Regarding the morphological parameters, increased expression of uPA was observed in the worst mode of invasion (p=0.03 ). The expression of uPAR was observed in 73.9% of cases in the front of invasion, with a predominance of score 1 (n=21; 45.6 %), and in 47.5% (n=21) of the cases in the center of the tumor, with a predominance of score 0 (n=25; 54.4%). Although no statistical differences were observed in relation to lymph node metastasis, clinical TNM staging, outcome, and histological grading, there was a higher expression of uPAR in cases with locoregional recurrence (p=0.04). Regarding the tumor intra -localization, it was observed an increased expression of uPA and uPAR at the front of invasion in relation to the center of the tumor (p<0.001). Regarding the correlation between uPA and uPAR, there was no statistical sign ificance. Based on these results, it is suggested that uPA and uPAR are involved in the progression of CELO, mainly in the deeper region of the tumor.

Avaliação da eficácia da radioterapia paliativa no controlo da dor em doentes com metástases ósseas

A Radioterapia é um dos tratamentos disponíveis para tratar o cancro seja com intuito curativo ou paliativo. O objectivo da radioterapia paliativa consiste em controlar os sintomas apresentados pelos doentes com doença avançada, como por exemplo a dor provocada pela presença de metástases ósseas, que é o sintoma em estudo neste trabalho. A Radioterapia deve causar o mínimo de efeitos secundários e o mínimo desconforto possível aos doentes, não devendo aumentar a morbilidade, mas antes proporcionar maior qualidade de vida aos doentes. Recentemente, vários estudos investigaram a utilização da radioterapia em fim de vida, proporcionando uma linha orientadora nesta área, a partir das condições clínicas dos doentes submetidos a radioterapia perto do final da vida. A escolha do tema deste trabalho resulta de uma inquietação sentida no dia-a-dia, aquando da realização dos tratamentos de radioterapia a doentes paliativos com dor óssea e com mau estado geral. Exigindo a radioterapia um posicionamento e imobilização precisos e rigorosos pode, por vezes, causar algum desconforto aos doentes. No caso dos doentes com necessidades paliativas, nomeadamente com dor moderada a forte, é importante inferir acerca do real benefício de um tratamento que ao invés de promover alívio, lhes pode provocar mais dor e desconforto, indo contra às boas práticas preconizadas em cuidados paliativos. Considera-se que o tema é relevante para a melhoria dos cuidados prestados ao doente oncológico a realizar tratamentos de radioterapia, na medida em que permite realizar uma reflexão acerca da eficácia deste tratamento em fim de vida e sua aplicabilidade quando estamos perante doentes com prognóstico de vida limitado. O estudo em causa é um estudo descritivo exploratório, tendo sido realizada uma análise sistemática da informação contida nos processos electrónicos dos doentes, disponíveis na rede hospitalar, de acordo com os critérios de inclusão estabelecidos, no sentido de averiguar a eficácia do tratamento de radioterapia no alívio da dor. O estudo permitiu concluir que a radioterapia é um tratamento eficaz no controlo da dor em doentes com metástases ósseas, não vindo alterar as conclusões avançadas por outros estudos e outros autores internacionais. No entanto, é importante a realização de um prognóstico mais preciso na tomada de decisão terapêutica para que doentes que não vão beneficiar do tratamento de radioterapia possam ser referenciados para cuidados paliativos mais precocemente. Quanto à escolha do esquema terapêutico, o esquema de fracção única deveria ser mais comummente utilizado pela sua demonstrada eficácia, como o comprovam os diversos estudos referenciados neste trabalho.

Chemokine Receptor Expression on Normal Blood CD56(+) NK-Cells Elucidates Cell Partners That Comigrate during the Innate and Adaptive Immune Responses and Identifies a Transitional NK-Cell Population

Studies of chemokine receptors (CKR) in natural killer- (NK-) cells have already been published, but only a few gave detailed information on its differential expression on blood NK-cell subsets. We report on the expression of the inflammatory and homeostatic CKR on normal blood CD56(+low) CD16(+) and CD56(+high)  CD16(-/+low) NK-cells. Conventional CD56(+low) and CD56(+high) NK-cells present in the normal PB do express CKR for inflammatory cytokines, although with different patterns CD56(+low) NK-cells are mainly CXCR1/CXCR2(+) and CXCR3/CCR5(-/+), whereas mostly CD56(+high) NK-cells are CXCR1/CXCR2(-) and CXCR3/CCR5(+). Both NK-cell subsets have variable CXCR4 expression and are CCR4(-) and CCR6(-). The CKR repertoire of the CD56(+low) NK-cells approaches to that of neutrophils, whereas the CKR repertoire of the CD56(+high) NK-cells mimics that of Th1(+) T cells, suggesting that these cells are prepared to migrate into inflamed tissues at different phases of the immune response. In addition, we describe a subpopulation of NK-cells with intermediate levels of CD56 expression, which we named CD56(+int) NK-cells. These NK-cells are CXCR3/CCR5(+), they have intermediate levels of expression of CD16, CD62L, CD94, and CD122, and they are CD57(-) and CD158a(-). In view of their phenotypic features, we hypothesize that they correspond to a transitional stage, between the well-known CD56(+high) and CD56(+low) NK-cells populations.

"Da ética e da circunstância do Abjeccionismo"

Estuda-se a metástase portuguesa do surrealismo que se chamou "Abjeccionismo" do ponto de vista da circunstância política da ditadura salazarista.